valu usd unless otherwis note
solid growth stori also healthi appreci
initi sp price target
view keytruda momentum set continu back host
upcom data read combin clear margin expans
opportun leav highli visibl growth growth also highli
appreci expect potenti surpris slow still
favor bias see room upsid limit back
recent strength initi sector perform price target
robust growth stori larg appreci street
model revenu ep compound-annual-growth-rate januvia
loe healthi growth also gener line consensu
like set-up concern upward keytruda
revis play margin stori becom central theme
albeit favor one reflect premium group
notabl sell-sid rate buy overal think
move higher see upsid limit level
expect keytruda remain steadi grower less driver
upward revis keytruda consensu forecast move higher
last month primari driver upward ep
revis stori continu product move
revenu compound-annual-growth-rate modestli
street outer year specif expect steadi growth
nsclc rcc non-lung indic potenti shift
adjuv opportun tnbc other follow
margin expans stori clear bake street model
hold expect invest year one
still deliv expans follow meaning move higher
margin improv basi point larg lower
oper expens still put us basi point
street equat ep leverag top-lin
growth import driver shift spend
portfolio non-growth reduc
understand bear case around keytruda loe concern
repres near-term valuat risk think earli
time see meaning sotp-driven upsid per
away known major loe keytruda loe leav
ampl time balanc sheet back-fil though keytruda
remain focu flipsid keytruda
npv sotp show meaning upsid even
aggress anim health comp dcf even
termin growth word upsid like driver
upsid perceiv valu
price prior trade day market close estimate unless otherwis note
invest thesi merck keytruda remain
key growth driver busi next sever
year declin busi segment continu
throw steadi cash strateg early-
stage deal augment pipelin diversifi busi
longer term thesi base follow key point
support sector perform rate
see continu strong growth ahead
keytruda still plenti runway loss
exclus loe concern becom urgent issu
seen stock sell year ahead meaning loe
cliff give merck plenti time
keytruda loe compani growth larg
driven keytruda sever tailwind
maintain momentum
bolt-on deal help diversifi mix augment
pipelin help compani navig keytruda loe
long runway loe limit urgenc near term
larger deal allow concentr bolt-on
strategi though uncertainti given pend ceo
transit also see room potenti portfolio prune
declin busi unit
merck margin expans stori compel
rel uniqu among peer continu oper
busi compani shift
primari care toward specialty/oncology/hospit focu
redirect spend effici segment
potenti catalyst data read focu phase
readout keytruda bladder
rcc sclc tnbc
pneumococc vaccin continu
busi develop augment pipelin new
ceo announc potenti portfolio prune
risk thesi competit risk keytruda
particularli nsclc bmy/azn greater-than-
expect price pressur busi greater
suppli pressur expect gardasil continu
limit growth ahead new manufactur come on-line
bloomberg capit market estim upside/downside/target
base-cas scenario see price target impli
price-to-earnings pro forma ep
assum keytruda remain primari growth driver
busi market leader nsclc
continu steadi oper margin expans
compani shift resourc away primari care
modest declin price across portfolio
specif built estim expect continu
capit deploy focus bolt-on deal dividend
growth stock repurchas
upside-cas scenario see price target impli
price-to-earnings pro forma ep
better-than-expect growth margin expans larg
driven keytruda
lack meaning competit challeng keytruda
specif built estim expect continu
capit deploy focus bolt-on deal dividend
growth stock repurchas
downsid case scenario see price target
impli price-to-earnings pro forma ep
greater competit impact keytruda expect
slower uptak key geographi china
wors price pressur anticip across portfolio
disappoint key pipelin data read
specif built estim expect continu
capit deploy focus bolt-on deal dividend
growth stock repurchas
opdivo/yervoy combo
threat keytruda nsclc
core segment
busi anim
women
divest spun/split
keytruda establish lead nsclc
unlik chang keytruda wide use well-character
analysi checkpoint inhibitor clinic trial show shift industri focu
checkpoint blockad combin regimen focu measur clinic benefit
combin chemotherapi watch full data set
poseidon trial expect read howev
base keytruda strong perform monotherapi trial among pd-
group think keytruda continu competit nsclc
question around segment core particularli around anim health
continu sourc on-going debat anim health segment
debat frequent given question around strateg overlap rest
busi one segment continu see growth along
oncolog vaccin primarili compani continu invest behind
busi seen recent acquisit antelliq argument
around trap valu well-understood particularli given pure-play anim
compani trade rich multipl ev consensu revenu
see exhibit impli portfolio concentr keytruda/oncolog without
anim health need meaning mean believ strateg
action around segment less like rel non-grow segment
ie women health believ merck view sourc cash flow
effect oper leverag shift spend innov busi
merck properli posit
benefit signific growth
opportun expect come
china meaning
geograph expans key grow product keytruda gardasil
lynparza lenvima remain import sourc growth go forward
keytruda ad nrdl still meaning
room grow self-pay market sale china compris
total revenu expect continu grow merck
china portfolio skew toward innov product grow rather
legaci drug current see pressur new value-bas
key pipelin driver
continu grow
merck two main loss
januvia keytruda
expect januvia loe put pressur model
continu year-over-year growth though modest
biggest driver growth model next sever year
keytruda opportun non-small-cel lung cancer key
driver well label expans particularli adjuvant/neoadjuv
indic geograph expans
aggress merck
capit deploy next
year compani
start ramp deal
anticip keytruda loe
merck clear strategi continu capit deploy
toward bolt-on early-stag deal focus innov augment pipelin
compani done deal last year abl
continu lever compani plan large-scal
see strateg benefit said ceo transit way
expect investor focu potenti large-scal remain pick
tabl content
sector perform price target portfolio manag summari
expect keytruda steadi grower better appreci street
solid oper margin stori also one well understood
bull case call sotp upsid struggl see forecast
bear case point loe concentr risk keytruda still earli
street sentiment overwhelmingli posit consensu long
price target impli upsid potenti
pipelin asset watch broaden busi
deriv cross-read els watch rel coverag
catalyst focu
import risk consid rel rate price target
financi model revenu build balanc sheet cash flow forecast
appendix closer look keytruda detail
sector perform price target portfolio manag summari
merck share continu move steadili higher back continu keytruda-
driven upward revis expect keytruda remain backbon merck
growth stori back host upcom data read ahead
becom compel margin-expans stori said understood
potenti upsid surpris limit view forecast meaning
differ consensu overal street sentiment overwhelmingli posit leav
stock consensu long bucket overal bia share favor room
upsid initi sector perform rate
exhibit forecast versu street model revenu ep cagr
expect keytruda steadi driver growth better appreci
keytruda repres revenu rise underscor
import product growth driver product grow
compound-annual-growth-rate growth driven continu penetr non-small-cel
lung cancer nsclc still room penetr non-
squamou nsclc squamou popul
monotherapi patient alk/egfr mutat keynote-
also signific opportun adjuvant/neoadjuv set
better understood data read next sever year npv work
keytruda per share major realiz ahead loss
exclus
solid oper margin stori one well understood core part stori
oper margin begin lift meaning beyond
manag point year invest though like look keep
expect strength keytruda-driven top line come
oper leverag seen sg compani shift spend away
legaci primari care asset keytruda program begin run
overal merck oper margin move
basi point higher put us basi point street
drive ep delta level upsid potenti via margin import
watch go forward
bull case call sotp upsid unlock valu via divestitur
struggl see forecast big part bull case relat sotp upsid
merck diversifi footprint sever valu driver think
sotp upsid debat keytruda anim health keytruda npv get us
per share realiz end still healthi tail
contribut loe signific focu sell-sid unlock
valu divest anim health debat around compar valuat asid comp
key driver street driven compound-annual-growth-rate modestli driven sg street annual
rang enterpris valu take midpoint get valu
divest busi may ultim right move unclear much
valu unlock
bear case point keytruda loe risk risk valuat impair
see yet think earli merck under-levered balanc
sheet rel attract pipelin long lead time address loe hit close
busi januvia/janumet introduc loe
model merck grow look major competitor
detail experienc loe-rel overhang celgen
case stock began see pressur roughli year even keytruda
consid extrem still see lot time ahead address merck clear
feel need pursu major new ceo
announc expect question like linger
look merck busi two bucket innov growth slow cash
flow gener exhibit detail innov growth product led keytruda
product rise revenu back
solid growth bigger share due declin rest busi look
merck continu add innov busi next sever year via
 pipelin deal
merck
total revenu
exhibit innov growth product increas total revenu
product declin still throw cash also take less oper
spend import part margin expans stori exhibit detail
legaci product mani face recent nuvar women
health expect merck deploy capit grow busi unless someth
compel came along said look model
compris total compani revenu
therapeut area total revenu total drive growth overallalli revenu aznalli revenu gardasil/gardasil constraint mute growthproquad/m-m-r health segment growth above-corpor antelliq dealcompanion new growth busi
exhibit merck slow cash flow gener in-declin product lower revenu
expect keytruda steadi grower better appreci street
revenu
move higher
busi
keytruda repres revenu set single-biggest
revenu driver next sever year signific room run
compound-annual-growth-rate driven label expans uptak
geographi primarili china steadi meaning upward revis street forecast
primari driver effect stock
adjuvant/neoadjuv remain larg opportun move forecast higher
think potenti upward revis limit modestli
street outer year per exhibit exhibit detail ep variabl
high-margin keytruda contribut matter drop bottom line ad
upsid forecast rel consensu larg off-set elsewher includ
margin assumpt
therapeut area total revenu total cagrcommentshospit acut gx entri other isentress/isentress zetia vytorin declin pressur loe drive larg pressur loe drive larg gener entri drive productsoth pharmaceuticaloth decline/slowingtot
exhibit modestli street outer year keytruda forecast million
continu see potenti penetr gain near term expect
keytruda growth driven continu penetr non-small-cel lung cancer
nsclc still room growth non-squam nsclc pd-
squamou popul monotherapi
patient alk/egfr mutat per exhibit
squamou popul repres market
per average per average consensu modestlyabov street drive ep upsid
exhibit continu see opportun keytruda penetr
recent approv indic drive continu growth includ
resect high-risk stage melanoma first adjuv approv iii
metastat small-cel lung cancer compris
lung cancer iv head neck squamou cell carcinoma
among other recent geograph expans europ china also key driver
china keytruda part nrdl merck believ
still huge opportun private/self-pay market recent ex-u launch
includ non-squam nsclc eu/china squamou
nsclc eu/china monotherapi china label
expans includ renal cell carcinoma eu exhibit reflect breakdown
us forecast indic
exhibit keytruda us sale indic model compound-annual-growth-rate us
rest-of-world label expans also import driver continu growth
come year lung cancer drive keytruda revenu ex-u see exhibit
geograph split reimburs europ non-squam nsclc
avail major european market china lung
remain under-penetrated opportun keytruda nation
reimburs drug list nrdl still meaning room grow
recent monotherapi approv meaning self-pay market
continu drive growth merck also point patient-access program help
expand avail annual diagnos lung cancer
countri key market think meaning contribut growth profil
product though competit chines launch sensit
around greater price pressur becom part nrdl re-ent strategi futur
date estim larg line street
exhibit ou drive keytruda estim million
overal expans continu drive meaning growth keytruda
compris vast major model revenu growth next sever year
see exhibit term increment revenu dollar growth year-over-year see
keytruda far greatest driver rest busi net drive
billion annual growth depict blue exhibit see rest
busi show net declin larg januvia loe though still model total
busi grow keytruda growth offset
exhibit keytruda compris revenu growth model million
expans adjuv popul drive long-term leg growth fulli
reflect street number fulli exclud adjuv melanoma first
seri adjuv expans opportun keytruda trial adjuv
neoadjuv underway meaning expand potenti target popul earli
stage major popul across differ cancer type gener
steadi stream data read come detail exhibit near term
focus triple-neg breast cancer adjuvant/neoadjuv studi
merck discuss regulatori author around determin path forward
nsclc adjuv studi primari read anticip
adjuvant/neoadjuv studi primari read model
revenu contribut million breast cancer risk-adjust likelihood
exhibit import keytruda data catalyst focu next coupl year
growth y/yrest businesskeytruda uskeytruda melanoma adjuv esophag adjuv neoadjuv mibc adjuv adjuv neoadjuv neoadjuv mibc local advancedhcc adjuv stage i/iia beyondtnbc neoadjuvant/adjuv melanoma neoadjuv adjuv adjuv local advanc local nmibc breast local advanc neoadjuv keytruda consensu
forecast next
sever year move
averag
sinc begin
ultim question whether merck continu deliv outsiz
keytruda revis seen exhibit sinc begin
seen street keytruda forecast year beyond push higher averag
close past year forecast move outsiz revis
continu merck share go follow think near term
watch detail around bristol astrazeneca poseidon
report posit top-lin result octob nsclc focus
measur risk/benefit combin checkpoint blockad
one hand bull case point limit adjuvant/neoadjuv contribut
built consensu ahead stream data read also acknowledg potenti risk
keytruda nsclc market share surviv benefit and/or
poseidon strong analysi trial us view
keytruda hold competit group addit focu ae
profil immunogen inher risk combin checkpoint blockad
demonstr clinic studi
exhibit keytruda street estim continu revis meaning higher time
model billion keytruda global sale encompass total
sale detail line item forecast indic separ
cancer har patient adapt immun system recogn target
tumor cell howev without system toxic chemotherapi agent offer
compel risk/reward profil despit checkpoint inhibitor market
physician check confirm prefer keytruda model
penetr peak across set penetr approv span
variou tumor line treatment bucket model indic cancer type
includ melanoma non-small-cel lung cancer nsclc small-cel lung cancer sclc
head neck squamou cell cancer hnscc bladder cancer microsatellit instabl high
msi-h renal cell carcinoma breast cancer tumor account risk-adjust
futur approv variou tumor tumor incorpor composit
preval rate take account basket tumor type
us revenu indicationdollar cell lung cancer indic think grow furthersmal cell lung cancer neck squamou cell instabl high cell carcinoma opportunityoth risk adjust nowtot us revenu model ou revenuedollar millionstot ou revenu model cagrgrowth total revenuetot risk-adjust ww revenu model cagrgrowth segment yoy growth analysi cell lung cancer cell lung cancer neck squamou cell instabl high cell carcinoma segment analysi cell lung cancer cell lung cancer neck squamou cell instabl high cell carcinoma vs ou revenu analysi pembrolizumab
solid oper margin stori also one well understood
oper margin
expans
merck clear margin expans stori primari driver keytruda
show exhibit expect overal trajectori oper margin mirror
keytruda revenu model rapid margin expans next year
correspond keytruda primari growth phase follow slower margin expans
thereaft keytruda matur along way expect temporari headwind
affect cadenc expans merck describ year
invest spend keytruda peak januvia/janumet lose
exclus billion revenu collect expect temporarili slow margin
expans told expect basi point oper margin expans
roughli come next three year clearli
impress margin stori basi point street equat
ep focu us also swing factor street forecast
segment analysi cell lung cancer cell lung cancer neck squamou cell instabl high cell carcinoma vs ou revenu analysi segment penetr individu indic cell lung cancer cell lung cancer neck squamou cell instabl high msi-h last-lin tumor colorect cell carcinoma axitinib canceradjuv pembrolizumab
exhibit expect next meaning step-up oper margin occur
increment expans thereaft
expect merck gener oper leverag across highest
contribut sg a/r exhibit detail bridg
oper margin expect margin increas basi point
biggest contribut come sg keytruda grow merck continu shift
spend away primary-car asset second-largest contributor deliv
basi point margin expans keytruda program start run
gross margin mute impact model basi point
margin expans
expect gross margin flat slightli next year sever
move part posit side expect growth keytruda gardasil
favor impact gross margin product carri above-corporate-averag margin
even high-single-digit royalti payment larg off-set
continu price pressur year-over-year price declin becom new normal
ii mileston payment go gross margin record becom
probabl expect remain meaning next year
biggest risk margin stori drug price and/or keytruda competit
disrupt former merck expect see increment price pressur
beyond saw trend unlik chang go forward
view said still expect gross margin expans least due mix
shift toward keytruda above-corporate-averag margin likewis expect
sg spend declin percentag sale time merck leverag
exist commercial/oper infrastructur keytruda program begin
wind
yearof invest weigh margin expansiona januvia/janumetlo
exhibit model bp oper margin expans
modestli
street margin
forecast basi
point roughli
believ margin stori well understood investor despit built
oper margin expans still basi point consensu per
exhibit equat ep overal margin expans remain
central theme merck sector rel model swing factor
think ep forecast rel consensu
exhibit modestli street outer year like remain focu
potenti upsid basi point equat roughli ep
bull case call sotp upsid struggl see forecast
ex-keytruda per
bull may point sum-of-the-part sotp analysi argu merck base busi
overlook under-valued given outsiz focu keytruda true
platform includ grow scale busi like anim health vaccin may
get attent deserv also includ therapeut area face
declin revenu and/or pend contribut littl way tail valu
 diabet immunolog women health put togeth deriv valu
per share base busi compar per share keytruda alon see
exhibit gener line dcf target point modest
upsid stock
keytruda worth forecast npv suggest per share per exhibit
assum discount rate growth termin growth declin
beyond year loe aggress termin growth declin reduc
npv per share
exhibit npv reflect per share valu keytruda tail valu compris
keytruda eros biosimilar beyond point becom focu
humira yet per exhibit npv
reflect npv valu tail base termin growth rate
open debat reflect view keytruda eros slower time
exhibit npv per share reflect much valu captur out-year
model compound-annual-growth-rate us/ouskeytruda total assum total drive meaning opex leverageopex rate tax treatment per earn callebi per npv per growth count base case year valu year
discount rest busi get roughli price target dcf
assum termin growth rate remaind busi word
find hard justifi meaning premium current stock price absent
aggress model assumpt howev assum termin growth rate
import assumpt drop current compound-annual-growth-rate non-
keytruda busi base busi valu drop per share
exhibit npv per share reflect much valu captur out-year
realiti merck clearli leader innov set becom
potenti best-sel drug keytruda sever busi make
footprint thu valu look growth exclud
keytruda grow remaind busi grow
believ busi deserv much premium rel peer current
stand anim health vaccin busi best-in-class scale franchis
compris one-third base busi contribut per exhibit total
revenu contrast diabet compris roughli
base today declin
revenu exclud
keytruda grow
annual
model
base businessbas busi per sharekeytruda valu per share
exhibit remain billion revenu exclud keytruda highli diversifi
grow low singl digit revenu compound-annual-growth-rate subject
notabl januvia/janumet nuvar isentress among other
merck unambigu view anim health core busi
expect question around potenti spin continu merck consid anim health
synergist part portfolio continu invest behind evidenc recent
acquisit antelliq vaki said believ would command
higher premium outsid merck two relev comp elanco zoeti
pure-play publicli trade anim health compani trade
ev consensu revenu per visibl alpha respect use multipl
bookend merck anim health busi could command anywher
stand-alone entiti midpoint shown exhibit realiti would
expect merck busi trade toward upper half rang base above-
market revenu compound-annual-growth-rate could yield much billion valu
challeng separ busi two-fold unclear merck would
replac growth without large-scal ii would increas keytruda
concentr unless issu address
expect merck sell spin busi
exhibit appli ev/sal multipl merck anim health busi yield valu
per share comp rang elanco zoeti
bear case point loe concentr risk keytruda still earli
bear case argu given merck larg pend loe relat keytruda
overhang like introduc stock valuat impair along
seen peer think earli still signific
time pursu busi develop ahead keytruda loe progress
pipelin without need pursu large-scal point nevertheless given
impact saw peer celgen even concern around
hit year debat around whether large-scal need remain
focu particularli merck like announc new ceo
merck rel manag januvia/janumet
bring impact point well understood
littl debat model merck grow manag messag
consist bigger focu merck prepar
year
exhibit merck major million
note exclud smaller product individu model
took closer look peer recent seen impact includ
celgen interestingli three pursu differ path respect
address major announc acquisit allergan address
pend humira biosimilar impact celgen sold bristol-my squibb ahead
revlimid gener entri pursu life-cycle strategi narcolepsi drug xyrem
merck largest loe dollar valu us compon loe rel
overal revenu base smaller other
exhibit revenu year expect us loe total revenu xyrem
concern merck face similar overhang other saw
see stock impact begin year loe case celgen
loe time known base prior settlement patent expir
previous valuat far merck loe concern began build
year loe saw valuat spread widen materi almost half
valu merck price-to-earnings basi per exhibit
revenu year loeou yearyear loe acquiringagn fill gap announc year loe toacquir announc year loe
exhibit price-to-earnings valuat celg move averag
bear case argu
merck could face
valuat stock
pressur seen peer
ahead respect
translat meaning under-perform versu drg per exhibit pressur
steadi perform rel drg peak roughli year
exhibit rel perform celg year us loe versu drg
far messag consist intent pursu larger
transact exhibit look recent commentari host differ
execut consist includ recent meet compani
exhibit manag consist clear interest pursu large-scal
given anticip ceo chang announc possibl expect
question linger lost us merck virtual larg pharma compani
announc close major transact potenti leadership
chang come lilli announc acquisit loxo oncolog bristol-my squibb
acquir celgen announc acquisit allergan made two big
move announc revers morri trust upjohn busi shrink
grow angl joint ventur consum busi glaxosmithklin
venuecommentoct mike nalli evp investor confer convers within compani think differ altern cost larg transact live merger merck schering-plough often time scientist spend coupl year priorit portfolio often time spend lot time worri job post merger feel realli strongli best use scientist time develop next gener breakthrough therapi probabl less inclin large-scal transact think everyth els realli fair game sept ken frazier chairman ceo investor confer want stress interest busi develop focus primarili futur scienc say think larg transact right thing merck right given thing roger describ think would disrupt organ way think would lose valu thing work intern jul ken frazier chairman earn call feel confid growth prospect go forward said past given interest particularli larg merger believ disrupt compani includ continu look bolt-on deal look across spectrum term size bolt-on divid dollar amount end day think oper complex cultur disrupt disrupt associ larg merger counsel go particularli feel confid abil grow compani organ supplement bolt-on deal jun ken frazier chairman ceo analyst meet larg deal think apertur broad term scan opportun honest think appetit gener speak less open reason believ first extraordinari opportun invest organ growth side worri disrupt opportun next year believ abundantli strong thing equal never -- never realli equal would say appetit less larg deal mid smaller deal
exhibit set bring new leadership ceo seat could influenc perceiv need pursu larg
transact ceo peer announc larg transact last year
merck still sever year posit keytruda loe past analog
predict word year would put time mid next four
year acquir develop next gener innov product drive
after-keytruda growth per exhibit
exhibit manag consist clear interest pursu large-scal
us keytruda keytruda analog month -celg began sell-off ahead us loe revlimidabbv-analog month -abbv began sell-off ahead us loe humira ou began oct analog began sell-off month aheadof us loe xyrem ou sale focusne identifi messag market strategi back-fil keytruda roughli one-third revenu base -debat pick around need larg deal
street sentiment overwhelmingli posit consensu long
merck share move steadili higher outpac drg per exhibit
sentiment gener bullish seen strong execut revenu
ep move higher quarter could continu least near term much
perform attribut continu beat-and-rais dynam seen
keytruda oper leverag brought
exhibit share continu steadili move higher outpac drg
share outpac
drg move like
pharma broadli
under-perform
street number revis continu higher last month see exhibit
merck rais guidanc everi quarter estim reflect strong
perform much driven keytruda growth show
exhibit seen consensu steadili revis higher keytruda beat street
last two quarter
-millionsstock performancevolumedrgpoli pelosi drug price propos phase data arqul deal announc
exhibit street ep estim move close higher sinc earli
street ep
climb steadili higher
close
sinc begin
sell-sid rate overwhelmingli bullish merck consensu long per exhibit
rate buy compar
moder modestli head earn sell-sid price target
continu drift higher offer median upsid overal street
sentiment remain much higher peer
exhibit sell-sid rate time rate overwhelmingli buy equival rate
price target impli upsid potenti
price target base equal blend ev/ebitda price-to-earnings
estim ev/ebitda get us per share price-to-earnings
get us per share use expect capit structur share count
offer modest upsid believ price target support sector perform rate
also ran discount cash flow analysi dcf get us per share larg
consist price target
price target
base price-to-earnings
ev/ebitda driven
large-cap pharma price
target multipl function large-cap pharma price target framework exhibit
start histor three-year industry-averag multipl adjust
company-specif factor adjust merck combin form discount
compani strong growth outlook off-set keytruda concentr risk
growth profil model ep compound-annual-growth-rate rank
toward high end peer see exhibit
loe risk concentr keytruda merck largest most-import
product far constitut revenu revenu
model need backfil revenu us/eu loe focu
plenti time
make adjust dividend yield repres
company-specif posit neg though anticip ceo transit worthi
consider merck histor devot larg dollar valu invest toward
busi develop rel peer moreov merck dividend yield fall near
midpoint peer
exhibit large-cap pharma price target framework company-specif adjust merck collect equat
valuat discount rel histor industri averag
p/eev/ebitda averagem track recorddividend yieldgrowth profilelo risk p/eev/ebitdashar cap net debtenterpris valueshar estimate net leverageimpliedotherpriceimplieddebt adj target adjust price target repres addit valu relat myl/viatri contribut captur estim averageadjust factor /- eachtot forecast impli ev/ebitda
dcf part price target calcul yield valu per share
dcf reflect explicit forecast termin growth rate beyond
use wacc consist across large-cap biopharma coverag
termin growth forecast reflect expect continu growth base
business/pipelin temper continu keytruda competit eros
exhibit dcf deriv valu per share wacc termin growth
merck trade modest premium large-cap biopharma peer find hard
argu meaning upsid keytruda opportun better understood
though like remain primari driver near term
exhibit merck trade price-to-earnings large-cap biopharma peer averag
pv termin valueperpetu growthenterpris equiti valueequ valu per
forecast above-averag growth merck beyond particularli
respect ep see exhibit larg driven keytruda revenu compound-annual-growth-rate
come above-corporate-averag gross margin
forecast revenu growth rate rest busi period less
loss exclus loe
januvia/janumet billion revenu
larg part pend
due
exhibit comparison large-cap biopharma revenu ep growth cagr
note revenu exclud upjohn contribut biopharma
factset capit market estim
merck dividend yield respect reason stock shown
exhibit offer better yield pure dividend play offer superior
combin growth yield view
exhibit comparison large-cap biopharma dividend yield merck fall roughli middl
merck share trade slight premium averag valuat per exhibit
fair valuat per large-cap pharma price target framework continu
exhibit merck histor valuat chart share trade slight premium averag
rel merck trade larg line histor averag per exhibit
drg typic trade within discount market trade today
pipelin asset watch broaden busi
beyond keytruda metastat cancer merck sever interest shot goal
compani run clinic trial adjuvant/neoadjuv set compani
focus access earlier line treatment market next chapter keytruda
growth although heavi exposur oncolog think hiv program interest
provid pipelin diversif virolog islatravir nucleosid revers
transcriptas transloc inhibitor phase infect hiv market
substanti world-wide preval estim million peopl live hiv
merck see market reach billion next year although earli think
could potenti bring uniqu valu proposit move phase
islatravir relebactam infectionheart infectionschizophreniabiliari us vaccinemelanomabreast cancervicriviroc eu colorect cancercerv cancerkeytruda solid tumorscolorect cancerlenvima eu biliari tract cancercutan squamou cell carcinomalynparza eu advanc solid eu cancergastr eu solid tumorsliv cancerselumetinib neurofibromatosi syncyti virusnasopharyng vaccineovarian cancerkeytruda eu small cell lung cancerlenvima eu endometri cancerlenvima cell lung cancerlynparza cancerlynparza cell lung cancergefapix vaccinephas reviewtherapeuticseg cardiovascular diseas diabet endocrinolog infecti diseas neurosci oncologyvaccin respiratori immunolog vaccin women
deriv cross-read els watch rel coverag
merck vast pipelin natur open potenti opportun deriv impact across
relat compani list relat program think could impact merck
catalyst readout includ within deriv cross-read tabl program
consid direct competitor base number factor includ treatment focu
mechan action think magnitud deriv impact list percent
revenu merck serv proxi determin rel magnitud impact
signific merck
exhibit deriv cross-read focus
companyproductwhat watchcommentsarq registr studi initi revers btk inhibitor develop hematolog malign acquisit expect close cover gregori renza arq studi cll sll nhl data primari complet date novemb arqul acquisit close revers btk-inhibitor competitor arq studi cll slll nhl data primari complet date decemb arqul acquisit close revers btk inhibitor program updat hpv rsv earli stage preclin program hpv rsv oral vaccin data hodgkin lymphoma potenti readout tumor agnost dataa solid tumor potenti readout inhibitor combo program solid durvalumab nsclc poseidon phase updat os result nsclc market studi chemotherapi combo nsclc estim primari complet date june squibbopdivo nivolumab nsclc checkmat phase updat result nsclc market alphaphas data solid tumor breast cancer expect readout protein target phase data merkel cell carcinoma phase data uterin cancer phase data anal cancer antibodi cover brian result solid tumor inhibitor combin studi melanoma estim primari complet date decemb stage program investig treatment benefit melanoma
catalyst focu
exhibit catalyst watch
datewhat phase data phase data bladder phase data breast phase pneu result pneumococc phase pneu-day studi adult increas risk mrkprimari complet prevnar phase pneu-way studi adult hivmrkprimari complet prevnar phase pneu-plan studi healthi infants/children/adolescentsmrkprimari phase chemo combo data nsclcbgneprimari mono recurrent/metastat cutan squamou cell carcinoma pdufa phase kestrel data head neck phase danub data bladder bayou phase data bladder yervoy concomit chemo phase full data ipilimumab checkmat phase studi complet head neck ipilimumab soc checkmat phase studi complet blader checkmat phase studi complet esophag checkmat phase studi complet phase phase pneu-sickl studi children sickl cellmrkprimari complet prevnar phase pneu-direct penu-p studi healthi infantsmrkprimari complet prevnar phase aegean data neo-adjuvant/adjuv phase data unresect stage phase himalaya data phase magellan data phase begonia data durvalumab tremelimumab addit chemo poseidon phase readoutaznkeytruda phase data head neck studi data readout rcc combo ipilimumab w/ chemo checkmat phase studi complet ipilimumab checkmat phase studi complet adjuv checkmat phase studi complet adjuv bladder cancerbmypt underw radic surgeri invas urotheli checkmat phase data adjuv lung nab-paclitaxel impass data neoadjuv impass data neoadjuv platinum base chemo impow data neoadjuv follow adjuv cisplatin base chemo impow data adjuv imvigor data adjuv nsclc phase
import risk consid rel rate price target
tail valu risk key loss exclus loe driven debat around
keytruda us/eu patent eu spc given high portfolio
concentr drug compris revenu grow
meaning word keytruda meaning
product portfolio also key growth driver strong gross margin
help buoy margin near term prior januvia/janumet loe also
concern though much lesser degre given smaller contribut
merck said expect compani abl grow loe
keytruda concentr key concern clearli long runway ahead
combin continu pipelin develop acquisit busi
develop strategi focus earlier-stag asset help mitig outer-
busi develop risk given merck expect remain activ busi
develop focus smaller earlier-stag asset find attract target
convert commerci opportun remain focu keytruda loe
still leav meaning runway portfolio concentr remain question
expect diversif reward said continu like focu
smaller earlier-stag asset acquisit partnership order build
broad pipelin begin convert ahead keytruda
loe similar strategi peer point go-forward basi
expect target valuat becom increasingli expens
pipelin risk merck continu activ develop pipelin keytruda
trial progress neoadjuvant/adjuv set alon across major tumor type
on-going trial around keytruda overal multipl program target
outsid keytruda recent deal tilo peloton immunedesign add
oncolog immunotherapi capabl pipelin success
convers opportun commercial-stag asset key concern
move closer loe
price risk sever propos bill around drug price reimburs
add uncertainti potenti risk group merck messag appear
reflect price declin expect greater
financi model revenu build balanc sheet cash flow forecast
exhibit revenu build
merck revenu us patent thru eu spc inject loe sep inject loe feb ped excl possibl allianc revenu astrazenecaunit revenu eisaiunit unit us patent thru eu spc lower stockpil proquad/m-m-r unit
exhibit revenu build contd
merck revenu acut us patent pend eu patent loe juli limit gx loe dec loe june loe certain market earli gener competit began loe april acut unit acut acut europ russia eu patent europ russia remain exclusivityimmunolog unit us patent japan patent unit us patent eu japan patent unit
exhibit revenu build contd
merck revenu loe dec loe japan loe loe april japan loe lead commerci right eu japan patent unit us/eu patent thru declin due continu price us patent eu patent unit gx launch expect other unit
exhibit revenu build contd
merck revenu remain exclus major marketunit patent major market expiredunit gener competitionunit loe market us japanfollistim eu japan formul patent expir unit risk-adjust new pipelineunit unit product longer disclosedtot unit unit net
exhibit
merck incom guid billion billioncost product profit guid opex increas primarili year invest oper incom guid opex higher mid-singl digitsinterest incom expens incom expens incom tax tax guid earn earn ep guid share share guid billion sharesdividend per yield base price base price targetebitda estimateebitda guid profit analysi guid growth share per
exhibit balanc sheet
merck balanc cash st receiv current current plant equip intang equityloan payabl current portion lt account current tax current incom non-current paid-in comprehens stock stockhold liabil
exhibit cash flow
merck statement item includ net intang incom adjust work flow oper sale net cash invest activ flow invest chang short-term issuanc treasuri paid exercis stock financ activ flow financ exchang rate chang chang cash equival begin equival end restrict equival ex
appendix closer look keytruda detail
keytruda largest valu driver estim reach sale drug
becom foundat treatment sever type tumor inhibit pd-
pathway sinc initi approv activ space
approv span sever tumor well-known biopharmaceut compani despit
competit bullish keytruda posit estim stabl
penetr rate see futur growth indic expans key market
breast prostat cancer addit think adjuvant/neoadjuv market
opportun underappreci see upsid opportun biggest risk remain
poseidon trial rel keytruda nsclc market share
keytruda broader label despit competit landscap keytruda
pembrolizumab program cell death protein approv global
treat differ tumor initi us approv took place metastat melanoma
sinc achiev broadest label among therapi
captur meaning share overal checkpoint blockad market opdivo
nivolumab market bristol-my squibb next largest world-wide
consensu estim billion addit sever approv
monoclon antibodi market
exhibit keytruda prevent cell exhaust block pathway
keytruda leverag adapt immun system drive cell-driven respons
key featur immun system abil recogn distinguish harm
foreign pathogen self necessari maintain balanc regulatori system
serv check balanc system axi
import pathway regul cell respons express
number lymphocyt cell includ cell produc quiescent state bound
respect ligand interact import prevent harm
overact autoimmun respons infect regul cell-medi
respons import tumor util regulatori pathway evad immun surveil
high-express level present tumor site creat quiet state
cell tumor site ad antibodi block interact
nsclc market meaning concern remain around outlook combin
regimen non-small-cel lung cancer nsclc common form lung cancer
respons million lung cancer patient diagnos million death
global year mani year advanced-stag patient treat
chemotherapy/radi and/or resect howev burdensom surviv
adapt immun respons shown promis outcom keytruda establish
prefer treatment success landmark keynot studi
studi set keytruda monotherapi use nsclc set
keytruda approv monotherapi nsclc april base find
valid keytruda monotherapi use
platinum-bas
chemotherapi nsclc patient tp score
import report os improv keytruda monotherapi versu platinum-
base chemotherapi patient tp score togeth find
establish keytruda lead role monotherapi use nsclc patient
tp score howev note greater efficaci patient higher tp
score final keytruda chemotherapi combo wide use nsclc set
demonstr clinic benefit patient low unknown statu
overal surviv compar
focu risk/reward profil cpi combin regimen await
full data poseidon trial despit lead
nsclc monotherapi chemotherapi combo increas focu pd-
combin trial increas significantli keytruda establish
lead therapi nsclc believ shift industri focu
combin regimen think could pose risk keytruda nsclc market
share meaning outcom report combin trial astrazeneca recent
announc achiev primari endpoint phase poseidon studi
compar imfinzi tremelimumab combin ad
chemotherapi vs chemotherapi treatment-nav nsclc stage-iv patient bristol-
myer squibb announc superior overal surviv vs chemotherapi phase
studi compar opdivo low-dos yervoy anti-ctla-
chemotherapi vs chemotherapi advanc nsclc
despit threat trial note increas toxic risk report
combin regimen observ combin registr
trial opdivo yervoy close monitor data read along
full dataset determin risk/benefit cpi combin
cross-trial comparison flaw look prior clinic trial suggest keytruda
hold upcom cpi-combin trial cross-trial comparison challeng
differ variabl trial design complic outcom reduc
compar howev look trial across competitor provid glimps
expect upcom trial although head-to-head studi
comparison across monotherapi produc greater one-year
compar opdivo tecentriq
compar grade regardless base discuss
kol believ combin regiment need demonstr
improv year surviv order warrant use despit increas toxic risk
although earli think cross-trial comparison suggest keytruda set high bar
hold competit group
keytruda look toward adjuvant/neoadjuv opportun next leg growth
posit increment data read could drive upsid minim data avail make
challeng model adjuvant/neoadjuv market opportun howev analyz
industri estim determin rel size compar metastat market
recent investor day event adjuvant/neoadjuv preval estim discuss
suggest metastat patient opportun although earli clinic develop
recogn scientif rational consid mechan action reliant cell-
mediat adapt immun base literatur discuss physician
immun respons tumor site like robust earli stage diseas
increas likelihood target earli patient monitor
look keytruda perform adjuv set tnbc patient includ risk-
adjust sale model final think success adjuvant/neoadjuv trial
upsid sale heavili risk-adjust street
exhibit meaning opportun adjuvant/neoadjuv market
